Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06381271

Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation

The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Aortic Valve Regurgitation Aortic Valve Disease Aortic Valve Insufficiency Cardiovascular Diseases Heart Diseases Heart Valve Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Pure native aortic valve regurgitation (NAVR) is a multifactorial valvular disease, with a prevalence of moderate or severe NAVR ranging from 0.5% to 2.7%. Patients with severe NAVR have a poor prognosis, conservative management has a 1-year mortality rate of more than 20%. Currently, surgical aortic valve replacement (SAVR) is the recommended treatment strategy for patients with NAVR. However, data showed that only 20% of patients with severe NAVR and left-ventricular ejection fraction (LVEF) of 30-50% undergo SAVR, while only 3% of those with an LVEF below 30% receive SAVR. Therefore, a less invasive surgical alternative therapy is needed for high surgical-risk patients from SAVR.

Transcatheter aortic valve replacement (TAVR) is now considered the first-choice treatment for elderly patients with aortic stenosis, regardless of surgical risk. Recently, it has also been used to treat patients with NAVR in an "off-label" setting. The latest European guidelines suggest that TAVR may be considered in experienced centers for selected patients with AR who are not eligible for SAVR. However, the role of TAVR in patients with severe NAVR is still debatable. Current studies on this topic are limited by their retrospective design and small sample sizes.

Dedicated devices for aortic regurgitation, such as the JenaValve, have shown promising results in terms of technical success and short-term outcomes. However, TAVR for patients with NAVR using on-label devices has a relatively high rate of pacemaker implantation. Additionally, the dedicated device was designed only for tricuspid valve anatomy, making TAVR with off-label devices the main invasive strategy for high-surgical risk patients with bicuspid valves. It's worth noting that the dedicated device is not yet commercially available worldwide. Therefore, further investigation into TAVR using off-label devices for NAVR patients, including those with bicuspid and tricuspid valves, is necessary.

The objective of this study was to evaluate the safety and efficacy of TAVR in patients with NAVR in a real-world setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.
  • 2. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form

Exclusion criteria

  • 1. Patients who cannot provide informed consent
  • 2. Patients who are treated with TAVR for aortic stenosis
  • 3. Patients who are participating in other clinical trials

Treatment and study plan

Transcatheter aortic valve replacement

Procedure

A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years

Other names: Transcatheter aortic valve implantation

Primary outcomes

  1. Combined clinical efficacy outcomes

    Time frame: 1 year

    Combined clinical efficacy outcomes as composed by all-cause mortality, all strokes, any hospitalization

Secondary outcomes

  1. Combined early safety and clinical efficacy outcomes

    Time frame: 30 days

    Composed by all-cause mortality, all strokes, life-threatening or fatal bleeding, major vascular, access-related, or cardiac structural complication, acute kidney injury stage 3 or 4, moderate or severe aortic regurgitation, new permanent pacemaker due to procedure-related conduction abnormalities, conduction block and arrhythmia, surgery or intervention related to the device, any hospitalization, myocardial infarction, any other adverse events

  2. Rate of technical success

    Time frame: at exit from procedure room

    • Freedom from mortality
    • Successful access, delivery of the device, and retrieval of the delivery system
    • Correct positioning of a single prosthetic heart valve into the proper anatomical location
    • Freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication

  3. Rate of device success

    Time frame: discharge or 30 days

    • Technical success
    • Freedom from mortality
    • Freedom from surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication
    • Intended performance of the valve (mean gradient<20mmHg, and less than moderate aortic regurgitation)

  4. Combined clinical efficacy outcomes

    Time frame: 2 years, 3 years, 4 years

    Combined clinical efficacy outcomes as composed by all-cause mortality, all strokes, any hospitalization

  5. Rate of all-cause mortality

    Time frame: 5years and 10years

  6. Valve-related long-term clinical efficacy

    Time frame: 5 years and 10 years

    • Freedom from bioprosthetic Valve Failure (defined as: Valve-related mortality OR Aortic valve re-operation/re-intervention OR Stage 3 hemodynamic valve deterioration)
    • Freedom from stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies)
    • Freedom from VARC Type 2-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents, used specifically for valve-related concerns (e.g. clinically apparent leaflet thrombosis)

Study contacts

Contact information is provided by the study sponsor or research team.

Rutao Wang, M.D, Ph.D

CONTACT

[email protected]

+86-15091095796

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Registry information

Official study title

Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation: a Real-world, Prospective, Multicenter Study (TRUST TAVR Registry)

Important dates

Study start
2018
Primary completion
2034
Study completion
2034
First posted
Apr 24, 2024
Registry last updated
Apr 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.